Developing Rapid Molecular Diagnostics | The Tej Kohli Cornea Program

James Chodosh, MD, MPH, holds the David G. Cogan Professorship in Ophthalmology in the field of Cornea and External Disease and is an associate director of the Infectious Disease Institute in the Department of Ophthalmology at Harvard Medical School.

The Tej Kohli Cornea Program at Massachusetts Eye & Ear, a teaching hospital of Harvard Medical School, aims to accelerate innovative and collaborative research to achieve unprecedented breakthroughs in corneal disease. The program pursues pathways to cure corneal blindness through prevention and treatment, including cutting-edge molecular technology for rapid diagnosis and early detection of corneal infection and GelCORE, an adhesive biomaterial for replacing corneal tissue.

Massachusetts Eye and Ear (MEE) is a teaching hospital of Harvard Medical School (HMS) and its Department of Ophthalmology is the world’s largest vision research and clinical enterprise. Between 2016 and 2018, MEE ophthalmologists conducted 521,805 patient visits and performed 101,941 ophthalmic surgeries and procedures. A long-time leader in research and clinical care for retinal disease, MEE performed the first FDA-approved gene therapy for an inherited disease in March 2018. Its clinician scientists are currently conducting more than 110 clinical studies and trials, in order to investigate new therapies across a broad array of vision disease and disorders.